Takeda Sued By Ex-Employee For Innovation That Led To Vitamin Line
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals is being sued by a 73-year-old former researcher for nearly $541,000, saying the $433 the firm paid him for his role in developing a vitamin B1 derivative was not enough. The man's discovery of an efficient way to obtain a key substance from the B1 vitamin derivative, fursultiamine, led to Takeda's highly successful line of Alinamin products. Takeda reported nearly $6 billion in sales from the Alinamin product line. The man received an additional $162 after 1998 and the firm's new program of compensation for on-the-job inventions. Takeda said it has fulfilled its obligations to the researcher. (Click here for more - a subscription may be required
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.